Dactinomycin: CAS No: 50-76-0 No: 50-76-0 Dactinomycin (or actinomycin D) was the very first known antibiotic that helped fend off cancer. It’s now a standard chemotherapy medication being used to treat a variety of tumorous diseases. Doctors will typically reach for dactinomycin for sarcoma, ovarian cancer, and Wilm’s tumor. It can also be used with certain types of neoplasia and skin moles. The[…]
Dactinomycin: An Old Chemotherapy API with New Demand
Antibiotic Tags: antibioticcancer treatmentchemotherapy Jan 16, 2019
Anti- Cancer Drug Volasertib Achieves Exemplary Results in Phase II Study
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: acute myeloid leukemiachemotherapy Jul 21, 2014
Boehringer Ingelheim recently shared exciting Phase II results from their anti-cancer breakthrough drug Volasertib. Patients enrolled in this landmark study, revealed July 8, 2014, had acute myeloid leukemia, or AML, and were considered to have unresectable cases. The study encompassed an elderly patient population, with every participant being over the age of 65. Results have[…]
Will Ibrutinib be the Next Major Breakthrough in Cancer Treatment?
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: chemotherapychronic lymphocytic leukemiaCLLIbrutinib Jun 25, 2013
Ibrutinib was a shining star in the pharmaceutical headlines on June 20, 2013, with the news that this experimental drug used to treat chronic lymphocytic leukemia may be the next breakthrough cancer treatment. As a medication Ibrutinib is different from the usual chemotherapy treatments in that it pointedly targets specific processes, and prevents tumor proliferation.[…]
New Phase III Trials to Begin for Trastuzumab in 2013
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1AnthracyclineschemotherapyHER2-positiveHerceptinTrastuzumab Jan 14, 2013
Exemplary results in the 2012 Phase III trial coined EMILIA has led Roche Pharmaceuticals to initiate additional Phase III trials evaluating trastuzumab emtansine. The New Year brings registration trials for newly diagnosed as well as previously treated metastatic HER2-positive breast cancer patients. Trastuzumab will be evaluated in this 2013 study for three settings in earlier-stage[…]
Pazopanib – Two FDA Approvals, Many Impressive Results
Chemotherapeutic / Anti-Neoplastic, FDA Approved 2009, FDA Approved 2012 Tags: chemotherapy Dec 17, 2012
Pazopanib, CAS number 635702-64-6, is an efficacious treatment for patients with advanced renal cell carcinoma, or RCC. As a type of cancer that begins in the cells of the kidneys, mainly in adults, Pazopanib is a reliable treatment in the class of medications called tyrosine kinase inhibitors. Pazopanib works by stopping or slowing the spread[…]
Ondansetron Offers Relief to Adult and Pediatric Patients
Antiemetic, Antipsychotic, Drug Research & Development API Tags: chemotherapyMethotrexateserotonin Mar 27, 2012
Ondansetronis also known by the brand name Zofran. As a medication used to prevent nausea and vomiting, geared especially for patients post chemotherapy, radiation or surgery, ondansetron is a 5-HT3 receptor antagonist. By blocking the activity of serotonin, a natural substance believed to cause nausea and vomiting, ondansetron is an effective antiemetic. Offered as a[…]
Gefitinib Continues to be a Viable Treatment Option for Patients with Non Small Cell Lung Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: chemotherapyWarfarin Mar 21, 2012
Gefitinib, CAS number 184475-35-2, is also known as the brand Iressa, which is marketed by AstraZeneca and Teva. Gefitinib is approved by the FDA to treat malignant and/or advanced non small cell lung cancer. Iressa has been shown to be effective in about 10% of clinical trial patients. LGM Pharma supplies gefitinib for R&D purposes,[…]
Temsirolimus Combo Therapy Increases Cancer Remission
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Immunosuppressant Tags: acute myeloid leukemiaAnnual Meetingcancer treatmentchemotherapy Jun 21, 2011
Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as[…]
Elacridar – A Unique Delivery System Fighting Chemotherapy Resistance
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: cancer treatmentchemotherapyDocetaxelimatinibIrinotecanPaclitaxel Jun 03, 2011
Elacridar, an ABCB1 modulator acting as a drug transporter, has been proven to have beneficial effects on the resistance of cancer cells to standard chemotherapeutic agents. This unique delivery system makes resistant cancers more susceptible to standard chemotherapeutic regimen. A study done by Ho Lun Wong et al showed beneficial results when Elacridar was used[…]
Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer
Monoclonal Antibodies / mAb Tags: 180288-69-1chemotherapyHER2-positiveHerceptinTrastuzumab May 16, 2011
A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]
- 1
- 2
